Cloud-Based Connectivity Platform Advances Decentralized Healthcare
|
By LabMedica International staff writers Posted on 03 Aug 2016 |
|
Image: Fionet connectivity with the Fio Deki Reader (Photo courtesy of Fio).
A novel reporting platform enables real-time oversight, fragile network connectivity, and actionable insights for medical device manufacturers and healthcare providers.
The Fio (Toronto, Canada) Fionet platform connects mobile companion devices that guide diagnosis, treatment, and record keeping with web-based tools for remote oversight and reporting. Fionet mobile software is designed for standard Android devices and the proprietary Deki Reader, a rugged, in vitro diagnostic (IVD) device for use with commercially available lateral flow immunoassays. As the Deki Reader provides step-by-step guidance for performing rapid diagnostic tests and delivers an objective analysis of results, Fionet provides test-by-test traceability.
As connectivity becomes an essential prerequisite for diagnostic platforms, Fionet meets the challenge by providing web-based tools for timely, accurate and complete record taking of individual patient visits; generating reports from aggregated, primary data; allowing two-way messaging with companion IVD devices; and easy data transfer and information technology (IT) integration. Fio will present the Fionet platform at AACC 2016.
“With healthcare services becoming more and more decentralized, device manufacturers are adapting their products from the lab outward. At Fio, we’ve built our data services from the field inward,” said Ian Fine, Chief Technology Officer of Fio. “Fio’s appearance at the AACC trade fair this year will provide an opportunity for the company to share insights from connecting diagnostics and data in developing countries.”
The American Association for Clinical Chemistry (AACC; Washington, DC, USA) is an international scientific/medical society of over 8,000 clinical laboratory professionals, physicians, research scientists and more. The AACC annual meeting, which will be held from July 31st to August 4th at the Pennsylvania Convention Center in Philadelphia (USA), features five days of educational sessions on scientific, clinical, technical and management challenges facing laboratory professionals, as well as the world’s largest Clinical Lab Expo.
Related Links:
Fio
American Association for Clinical Chemistry
 Assay.jpg)
The Fio (Toronto, Canada) Fionet platform connects mobile companion devices that guide diagnosis, treatment, and record keeping with web-based tools for remote oversight and reporting. Fionet mobile software is designed for standard Android devices and the proprietary Deki Reader, a rugged, in vitro diagnostic (IVD) device for use with commercially available lateral flow immunoassays. As the Deki Reader provides step-by-step guidance for performing rapid diagnostic tests and delivers an objective analysis of results, Fionet provides test-by-test traceability.
As connectivity becomes an essential prerequisite for diagnostic platforms, Fionet meets the challenge by providing web-based tools for timely, accurate and complete record taking of individual patient visits; generating reports from aggregated, primary data; allowing two-way messaging with companion IVD devices; and easy data transfer and information technology (IT) integration. Fio will present the Fionet platform at AACC 2016.
“With healthcare services becoming more and more decentralized, device manufacturers are adapting their products from the lab outward. At Fio, we’ve built our data services from the field inward,” said Ian Fine, Chief Technology Officer of Fio. “Fio’s appearance at the AACC trade fair this year will provide an opportunity for the company to share insights from connecting diagnostics and data in developing countries.”
The American Association for Clinical Chemistry (AACC; Washington, DC, USA) is an international scientific/medical society of over 8,000 clinical laboratory professionals, physicians, research scientists and more. The AACC annual meeting, which will be held from July 31st to August 4th at the Pennsylvania Convention Center in Philadelphia (USA), features five days of educational sessions on scientific, clinical, technical and management challenges facing laboratory professionals, as well as the world’s largest Clinical Lab Expo.
Related Links:
Fio
American Association for Clinical Chemistry
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
POC Immunoassay Analyzer
Procise DX
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Latest AACC 2016 News
- Molecular Test Detects Three Arboviruses in Plasma Samples
- Derived Exosomal Protein Biomarkers in Alzheimer’s Disease Diagnosis
- New Biochip Array Developed for ApoE4 Classification
- Cell-Free DNA Identifies Liver Transplant Patients with Acute Rejection
- New Method Tested for Early Diagnosis Pediatric Diabetic Nephropathy
- FDA-Cleared Automated Cell Counter for CSF Launched at AACC 2016
- Semen Analysis Portfolio with Two New Products Featured at AACC 2016
- Automation Solutions for Clinical Diagnostic Equipment Showcased at AACC 2016
- New Tubes Designed for Medium Sample Volumes
- Multi Sample Osmometer Improves Testing Efficiency
- Innovative Information System Optimizes Laboratory Processes
- Innovative eLearning Interface Seamlessly Connects Competency Data
- Adhesives Research to Present Hydrophilic Adhesive Technologies
- Point-of-Care Immunoassay Analyzer on Display at AACC Annual Meeting
- Assay for Determination of 17-OH Progesterone to Be Featured at AACC Annual Meeting
- Fully Automated HbA1c Analyzer Available for Inspection at AACC Annual Meeting
Channels
Clinical Chemistry
view channel
Blood Hormone Pattern Distinguishes Endometriosis with High Accuracy
Endometriosis occurs when tissue similar to the uterine lining grows outside the womb, triggering inflammation, pain, and scarring. Diagnosis often relies on surgery and, in the UK, takes an average of... Read more
Blood Test Brings Alzheimer’s Biomarker Assessment to Routine Labs
Beckman Coulter Diagnostics has received CE Mark under IVDR for the Access p‑Tau217 assay, a blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms... Read more
Molecular Diagnostics
view channel
Epigenetic Profiling Could Refine Prognosis in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with heterogeneous biology that complicates prognostication and treatment selection. Genetic testing clarifies many drivers, yet it... Read more
Genetic Risk Score Supports Diagnosis and Prognosis in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) causes progressive, irreversible lung scarring that limits breathing and can lead to death. More than 100,000 Americans live with IPF, and an estimated 30,000–40,000... Read more
Extracellular Vesicle Marker Identifies Early Lung Adenocarcinoma and Predicts Recurrence
Lung cancer remains a leading cause of cancer death, and early-stage disease often produces few symptoms, complicating timely diagnosis and risk stratification. Conventional imaging and tissue biopsy have... Read more
Hematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read more
Immunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
CE-Marked Blood Assay Automates Tuberculosis Infection Testing
Tuberculosis continues to pose a major global health challenge, with an estimated 10.7 million people falling ill and 1.23 million deaths in 2024. Roughly one quarter of the world’s population is believed... Read more
Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
Genomic surveillance is essential for detecting viral variants before they spread widely, yet many public health systems face high costs, uneven capacity, and computational barriers. Existing analytic... Read more
Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
Acute infectious gastroenteritis remains a major cause of illness worldwide, especially in young children, older adults, and immunocompromised patients. Nonspecific symptoms such as diarrhea, vomiting,... Read more
H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read morePathology
view channel
New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
Recurrent breast cancer remains a persistent driver of morbidity and retreatment, and current risk stratification often depends on genomic assays that are costly and slow. Waiting weeks for results can... Read more
EBV Status Helps Predict Survival in Primary CNS Lymphoma
Primary central nervous system lymphoma is a rare malignancy in which tumors arise in the brain and, less often, the spinal cord, eyes, or cerebrospinal fluid. Outcomes are especially variable when the... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
Industry
view channel
Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Colombia remains a high-priority setting for tuberculosis, with a growing need for diagnostics that complement existing testing strategies and improve access to earlier diagnosis. Solutions that function... Read more
